- Home
- BIIB vs CSGP Comparison
BIIB vs CSGP Comparison
Compare BIIB & CSGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIIB | CSGP |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9B | 13.1B |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BIIB | CSGP |
|---|---|---|
| Price | $223.26 | $27.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 35 | 21 |
| Target Price | ★ $238.18 | $37.30 |
| AVG Volume (30 Days) | 918.1K | ★ 5.3M |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.15 | 0.14 |
| Revenue | ★ $9,890,600,000.00 | $965,230,000.00 |
| Revenue This Year | $5.59 | $16.66 |
| Revenue Next Year | $2.05 | $11.38 |
| P/E Ratio | ★ $103.64 | $198.00 |
| Revenue Growth | 2.22 | ★ 15.23 |
| 52 Week Low | $138.00 | $25.89 |
| 52 Week High | $230.49 | $81.43 |
Technical Indicators
Market Signals| Indicator | BIIB | CSGP |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 37.67 |
| Support Level | $184.50 | $26.29 |
| Resistance Level | $225.80 | $31.41 |
| Average True Range (ATR) | 5.07 | 0.96 |
| MACD | -0.11 | -0.17 |
| Stochastic Oscillator | 56.58 | 18.79 |
Price Performance
Historical ComparisonAbout BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About CSGP CoStar Group Inc.
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.